0001209191-13-040980.txt : 20130815 0001209191-13-040980.hdr.sgml : 20130815 20130815181322 ACCESSION NUMBER: 0001209191-13-040980 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130813 FILED AS OF DATE: 20130815 DATE AS OF CHANGE: 20130815 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ONCOGENEX PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000949858 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 954343413 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1522 217TH PLACE S.E. CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254879500 MAIL ADDRESS: STREET 1: 1522 217TH PLACE S.E. CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: SONUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950825 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wyrick Susan D. CENTRAL INDEX KEY: 0001568605 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 033-80623 FILM NUMBER: 131043392 MAIL ADDRESS: STREET 1: 1522 217TH PLACE SE STREET 2: SUITE 100 CITY: BOTHELL STATE: WA ZIP: 98021 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2013-08-13 0 0000949858 ONCOGENEX PHARMACEUTICALS, INC. OGXI 0001568605 Wyrick Susan D. 1522 217TH PLACE SE SUITE 100 BOTHELL WA 98021 0 1 0 0 PAO Common Stock 2013-08-13 4 M 0 1363 0.00 A 1363 D Common Stock 2013-08-13 4 F 0 372 0.00 D 991 D Restricted Stock Unit (RSU) 2013-08-13 4 M 0 688 0.00 D 2016-07-29 Common Stock 688 2062 D Restricted Stock Unit (RSU) 2013-08-13 4 M 0 675 0.00 D 2014-04-30 Common Stock 675 1672 D Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. Represents shares of common stock that have been withheld by the issuer to satisfy the income tax withholding and remittance obligations in connection with the net settlement of the RSUs, based on the close price of $9.32 per share on August 12, 2013. Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement. Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest on August 13, 2013 and then annually on the later of: (i) each anniversary of June 29, 2012; and (ii) the first day thereafter during which the issuer's trading window is open. Pursuant to the terms of the RSU, 100% of the total shares underlying the RSU vest on the later of (i) achievement of both the successful enrollment and release of data from certain clincial trails, and (ii) the first trading day thereafter on which the issuer's trading window is open, although less than 100% of the total shares may vest upon the achievement of certain, but not all, of the milestones. Sandra Thomson as attorney-in-fact for Susan Wyrick 2013-08-15